<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="869">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192698</url>
  </required_header>
  <id_info>
    <org_study_id>04-05-09A</org_study_id>
    <nct_id>NCT01192698</nct_id>
  </id_info>
  <brief_title>Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus</brief_title>
  <official_title>Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolinas Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carolinas Healthcare System</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to prevent liver allograft infection with Hepatitis C virus
      in hepatitis C positive patients undergoing liver transplantation. The hypothesis is that
      patients who receive ribavirin immediately before transplant and intravenous interferon alfa
      2b during the anhepatic phase(while the liver is removed)will have sustained virologic
      response post liver transplant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HCV RNA result</measure>
    <time_frame>Measured at specified intervals up to one year post transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will measure HCV RNA levels pre-transplant, during and post-transplant up to one year.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>IV interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV interferon oral ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV interferon</intervention_name>
    <description>IV interferon 5MU during anhepatic phase</description>
    <arm_group_label>IV interferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver transplant for hepatitis c

        Exclusion Criteria:

          -  allergy to interferon
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark W Russo, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carolinas Healthcare System</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>August 30, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carolinas Healthcare System</investigator_affiliation>
    <investigator_full_name>Mark W. Russo</investigator_full_name>
    <investigator_title>Medical Director of Liver Transplantation</investigator_title>
  </responsible_party>
  <keyword>hepatitis c</keyword>
  <keyword>liver transplant</keyword>
  <keyword>hepatitis C after liver transplant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
